IceCure Medical Ltd.
7 Ha'Eshel St.
Southern Industrial Park
15 articles with IceCure Medical Ltd.
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure's Cryoablation Products
IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
Recently Reported Preliminary First-Half 2020 Sales Were x3 Higher than Same Period in 2019, Demonstrating Significant Growth as Cryoablation Technology Continues to Gain Global Awareness
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement With MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors
New Territory in Singapore with Global Medical Leader, Terumo, Marks Successful Partnership Progress in Executing Milestone Distribution Agreement
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
Following the additional U.S. Food and Drug Administration clearance for its Cryoablation Technology, IceCure Medical Ltd., an Israeli medical device company, developers of a non-surgical Liquid Nitrogen cryoablation technology to destroy benign and cancerous tumors by freezing, plans to significantly extend its U.S. operations in target markets for indications with existing CPT codes and reimbursement.
IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, announced today an exclusive distribution agreement with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY: OTC US)
IceCure Medical Presents Promising Results from First-ever Interventional Radiology Study With Its Next Generation Liquid Nitrogen (LN2) Cryoablation System, ProSense™
Data presented at the European Association of Urology showed the ProSense™ system at 1-year follow-up was safe, effective and without serious adverse events for treating small kidney tumors
IceCure Medical Ltd. Release: National Multi-Center Clinical Trial Of Non-Surgical Breast Cancer Treatment Enrolls First Patients
IceCure Medical Ltd. Announces Treatment of First Breast Cancer Patient Using Its IceSense3 Cryoablation System at John Wayne Cancer Institute
IceCure Medical Ltd. Enters a New High-Potential Market: the Company Received $100K-Order for Cryoablation Consoles and Probes to be Used in a Clinical Study for the Treatment of Lung Cancer
Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund